Gå til hovedindhold
UdbudsScanner
Alle udbud
TED742935-2024

MACSima instrument

Ordregiver
Københavns Universitet
Oplyst værdi / estimat
1.826.147 DKK
Frist
—
Publiceret
5.12.2024
CPV
38000000
Leveringssted (NUTS)
DK011, DNK

Dataposten opdateret . Datakilder, dækning og beregningsmetode.

Tildeling

Vinderlisten dækker bekendtgørelsen. Denne visning har ikke en sikker kobling mellem hver vinder, delkontrakt, værdi og udløbsdato. Se originalen for fordelingen.

Bekendtgørelsens samlede værdi: 1.826.147 DKK
Miltenyi Biotec Norden AB
Registreringsnr. 556873-8545Oplyst værdi: 1.826.147 DKK

Beløb er offentliggjorte værdier i bekendtgørelser og kan omfatte flere delkontrakter, rammeaftalelofter og estimater. De viser ikke faktisk omsætning eller forbrug. Valutaer summeres hver for sig uden omregning. Manglende beløb er ikke nul. Se datagrundlag og metode.

Beskrivelse
BRIC has chosen to accept the offer from Miltenyi Biotec] as, we believe that only the MACSIMA platform from Miltenyi Biotec is addressing our needs sufficiently. We need a multiplex staining platform with minimal tissue damage afflicted during each cycle and an efficient software to stitch the partial images, to subtract background lfuorescence, and to analyze the complete images. Only the MACSIMA platform showed that it can stain more than 400 markers without detectable loss of quality, which is unmatched by other products. Furthermore, the iQView software used for running the platform as well as for analyzing the images is both robust as well as powerful, and to our mind better than those of potential alternative products. Therefore we are not interested in acquiring any other multiplex immunofluorescent staining platform currently available on the market. The reason for the purchase is to allow us immediate access to this breakthrough technology.

Procedure og udbudsmateriale

Oplysninger fra bekendtgørelsen kan dække flere delkontrakter. Listerne nedenfor er separate uddrag; rækkefølgen kobler ikke et kriterium til en beskrivelse eller delkontrakt. Kontrollér krav, vægtning, frister, optioner og eventuelle rettelser i originalmaterialet.

Proceduretype (kildens kode)

  • neg-wo-call

Tildelingskriterier

  • Forskningsresultater

Beskrivelser af tildelingskriterier

  • BRIC has chosen to accept the offer from Miltenyi Biotec] as, we believe that only the MACSIMA platform from Miltenyi Biotec is addressing our needs sufficiently. We need a multiplex staining platform with minimal tissue damage afflicted during each cycle and an efficient software to stitch the partial images, to subtract background lfuorescence, and to analyze the complete images. Only the MACSIMA platform showed that it can stain more than 400 markers without detectable loss of quality, which is unmatched by other products. Furthermore, the iQView software used for running the platform as well as for analyzing the images is both robust as well as powerful, and to our mind better than those of potential alternative products. Therefore we are not interested in acquiring any other multiplex immunofluorescent staining platform currently available on the market. The reason for the purchase is to allow us immediate access to this breakthrough technology.
Åbn originaludbud

Andre bekendtgørelser i samme CPV-kategori

Nyeste bekendtgørelser med samme firecifrede CPV-kategori. Listen kan omfatte både åbne udbud og historik.